Page 16 - Biyolojik Ajan Kullanan Romatolojik Hastalarda Enfeksiyon Yönetimi

Biyolojik Ajan Kullanan Romatolojik Hastalarda Enfeksiyon Yönetimi

dıktan sonra biyolojik ajanların uygulanmasıdır (15). Ancak 7. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granu-
olgu bazında tedavi bireyselleştirilebilir. Aktif tüberküloz sap- lomatous infectious diseases associated with tumor necrosis factor
tanan hastalarda standart tüberküloz tedavisi başlanır, bildirim antagonists. Clin Infect Dis 2004;38:1261-5.
yapılarak “verem savaş dispanserleri”ne yönlendirilir. 8. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et
al. Gamma interferon release assays for detection of Mycobacterium
Anti-TNF tedavi kesildikten sonra TB riski devam edebilir. Bu tuberculosis infection. Clin Microbiol Rev 2014;27(1):3-20.
nedenle hastaların TB yönünden en az 6 ay daha takip edilme- 9. T.C. Sağlık Bakanlığı. Tüberküloz Tanı ve Tedavi Rehberi. 2 Baskı An-
si uygundur. kara, Mayıs 2019.
10. Menzies D. Approach to diagnosis of latent tuberculosis infection
(tuberculosis screening) in adults. Available from: https://www.upto-
KaynaKLar
date.com/contents/approach-to-diagnosis-of-latent-tuberculosis-in-
1. Baddley JW, Cantini F, Goletti D, Gomez-Reino JJ, Mylonakis E, San-Ju- fection-tuberculosis-screening-in-adults. Erişim tarihi: 20.03.2021.
an R, et al. ESCMID Study Group for Infections in Compromised Hosts 11. Comstock GW, Baum C, Snider DE. Isoniazid prophylaxis among Alas-
(ESGICH) Consensus Document on the safety of targeted and biologi- kan Eskimos: a final report of the bethel isoniazid studies. Am Rev
cal therapies: an infectious diseases perspective (Soluble immune ef- Respir Dis 1979;119(5):827-30.
fector molecules [I]: anti-tumor necrosis factor-a agents). Clin Micro- 12. Menzies D. Use of the tuberculin skin test for diagnosis of latent
biol Infect 2018;24(2):S10-S20.
tuberculosis infection (tuberculosis screening) in adults. Available
2. Anton C, Dominguez-Machado F, Ahumada Ramirez JM, Bernardi RM, from: https://www.uptodate.com/contents/use-of-the-tubercu-
Palominos PE, Brenol CV, et al. Latent tuberculosis infection in patients lin-skin-test-for-diagnosis-of-latent-tuberculosis-infection-tubercu-
with rheumatic diseases. J Bras Pheumol 2019;45(12);e20190023. losis-screening-in-adults. Erişim tarihi: 20.03.2021.
3. Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. Risk of 13. Hasan T, Au E, Chen S, Tong A, Wong G. Screening and prevention for
tuberculosis reactivation in patients with rheumatoid arthritis, anky- latent tuberculosis in immunosuppressed patients at risk for tuber-
losing spondylitis, and psoriatic arthritis receiving non-anti-TNF-tar- culosis: a systematic review of clinical practice guidelines. BMJ Open
geted biologics. Mediators Inflamm 2017;2017:8909834. 2018;8e022445.
4. Holroyd CR, Seth R, Bukhari M, Malaviya A, Holmes C, Curtis E, et al; 14. Horsburgh CR. Treatment of latent tuberculosis infection in HIV-unin-
for the British Society for Rheumatology Standards, Guidelines and fected nonpregnant adults. Available from: https://www.uptodate.
Audit Working Group. The British Society for Rheumatology biologic com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-u-
DMARD safety guidelines in inflammatory arthritis-Executive sum- ninfected-nonpregnant-adults. Erişim tarihi: 20.03.2021.
mary. Rheumatology (Oxford) 2019;58:e3-e42.
15. Singh JA, Saag KG, Bridges Jr SL, Akl EA, Bannuru RA et al; American
5. Winthrop KL. Tumor necrosis factor-alpha inhibitors and mycobacte- College of Rheumatology. 2015 American College of Rheumatology
rial infections. Available from: https://www.uptodate.com/contents/ Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care
tumor-necrosis-factor-alpha-inhibitors-and-mycobacterial-infecti- (Hoboken) 2016;68(1):1-25.
ons. Erişim tarihi: 20.03.2021.
16. Ormerod LP, Milburn HJ, Gillespie S, Ledingham J, Rampton D. BTS re-
6. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A; B commendations for assessing risk and for managing Mycobacterium
S R B R Control Centre Consortium, D P M Symmons, on behalf of the tuberculosis infection and disease in patients due to start anti-TNF-α
BSR Biologics Register Drug-specific risk of tuberculosis in patients treatment. Thorax 2005;60:800-5.
with rheumatoid arthritis treated with anti-TNF therapy: Results from
the British Society for Rheumatology Biologics Register (BSRBR). Ann
Rheum Dis 2010;69:522-8.

6